Visceral Adipose Tissue (VAT): When to Order This Test

What Visceral Adipose Tissue (VAT) Actually Means

Visceral adipose tissue is the fat stored inside the abdominal cavity, tucked between and around organs such as the liver, pancreas, and intestines. Unlike subcutaneous fat, which sits just beneath the skin, VAT is hormonally and metabolically active in ways that directly worsen insulin signaling, systemic inflammation, and lipid metabolism.

Why VAT Differs from Subcutaneous Fat

Subcutaneous fat acts partly as an energy buffer. VAT, by contrast, releases free fatty acids and pro-inflammatory adipokines directly into the portal circulation. This portal delivery exposes the liver to a sustained lipotoxic signal, driving hepatic insulin resistance and elevated VLDL-triglyceride output. A 2012 analysis published in Obesity Reviews confirmed that visceral fat mass correlates with hepatic fat content independently of total body fat percentage (Fabbrini et al., PMID 22004045).

How VAT Is Quantified

The reference-standard imaging method is CT cross-sectional area at the L4-L5 vertebral level, reporting VAT in cm². DEXA with a dedicated body-composition software module (GE Lunar iDXA, Hologic Horizon) offers a validated, lower-radiation alternative. DEXA-derived VAT area correlates with CT-derived VAT area at r = 0.87 to 0.93 in validation studies (Kaul et al., PMID 22855493). MRI remains the most precise method but is cost-prohibitive for routine screening.

What the Numbers Mean

DEXA software typically reports VAT as a mass in grams and an estimated area in cm². Sex-specific reference ranges from Hologic normative data and published cohort studies place low-risk thresholds at roughly <100 cm² for women and <160 cm² for men. Values above these thresholds track with increasing prevalence of metabolic syndrome components: hypertriglyceridemia, low HDL-cholesterol, elevated fasting glucose, and hypertension (Després and Lemieux, PMID 17167477).

When to Order a VAT Measurement

The test is most useful when BMI or waist circumference gives an incomplete picture of a patient's true cardiometabolic burden. Standard BMI classifies a patient as "overweight" or "obese" based on weight-to-height ratio, with no information about fat distribution or organ-specific risk.

Patients Who Benefit from VAT Testing

Normal-weight obesity. A patient with BMI 22-24.9 but high body-fat percentage and a family history of type 2 diabetes may carry substantial occult visceral fat. This phenotype, sometimes called "TOFI" (thin outside, fat inside), is missed entirely by BMI-based screening. One cross-sectional study in Journal of the American College of Cardiology (N=6,809) found that 30% of normal-BMI adults had metabolic obesity defined by elevated VAT (Oliveros et al., PMID 24216628).

Pre-diabetes and insulin resistance. The American Diabetes Association 2024 Standards of Care recommend body-composition assessment as an adjunct to fasting glucose and HbA1c when risk stratification is uncertain (ADA Standards 2024, Section 3). Elevated VAT predicts progression from pre-diabetes to type 2 diabetes independent of BMI.

Non-alcoholic fatty liver disease (NAFLD) / MASLD. Patients with elevated liver enzymes or ultrasound-confirmed hepatic steatosis benefit from VAT quantification because visceral fat drives hepatic lipotoxicity. Knowing the VAT burden helps clinicians set intensity-of-intervention targets.

Polycystic ovary syndrome (PCOS). PCOS is associated with preferential visceral fat accumulation even in lean women. The Endocrine Society 2023 PCOS guideline notes that metabolic risk assessment should go beyond BMI in this population (Endocrine Society PCOS Guideline).

Hypogonadism (male and female). Low testosterone in men and estrogen deficiency in postmenopausal women both shift fat distribution toward the visceral compartment. VAT measurement helps clinicians document baseline status before and after hormone therapy initiation.

Statin-eligible but borderline-risk patients. When a 10-year ASCVD score falls in the 7.5-10% "discuss" zone, high VAT can tip the shared decision-making conversation toward more aggressive lipid management, consistent with ACC/AHA 2019 Cholesterol Guidelines (Grundy et al., PMID 30423391).

When VAT Testing Adds Little

VAT measurement is less likely to change management in patients with established cardiovascular disease, frank obesity (BMI >35) already qualifying for intensive therapy, or in those already committed to a GLP-1 receptor agonist or bariatric pathway regardless of imaging findings. In these cases, the test result would not alter the treatment decision.

Practical Ordering Considerations

Order VAT as part of a full DEXA body-composition scan. Request the "visceral adipose tissue" or "android/gynoid" report specifically; not all DEXA facilities activate the VAT algorithm by default. Pair the result with a fasting lipid panel, fasting insulin, HbA1c, and a blood pressure measurement on the same visit to interpret risk holistically.

Normal VAT Range: What the Reference Data Show

No single universally adopted VAT cutoff exists across all guidelines, but three converging evidence streams provide actionable reference points.

Population-Based Thresholds

The most cited boundary in cardiometabolic research is a VAT area of 100 cm² for women and 160 cm² for men, derived from cross-sectional analyses linking these thresholds to a twofold or greater prevalence of metabolic syndrome (Desprès et al., PMID 17167477). Some researchers use a single sex-combined threshold of 100 cm² for elevated risk in women, while men tolerate somewhat higher VAT before equivalent metabolic deterioration appears, reflecting known hormonal differences in fat partitioning.

Age and Ethnic Considerations

VAT accumulates with age in both sexes, particularly after menopause in women and after age 40 in men. South Asian, East Asian, and Hispanic populations tend to develop metabolic complications at lower VAT volumes than European-descent populations, suggesting that ethnicity-specific thresholds are clinically appropriate (Wen et al., PMID 19318035). The AACE Obesity Algorithm 2023 explicitly recommends lower waist-circumference cut points for Asian patients, a principle that extends to VAT interpretation (AACE Obesity Algorithm 2023).

How Hologic and GE DEXA Systems Report VAT

Hologic Horizon and GE Lunar iDXA both produce a VAT mass estimate (grams) and a VAT area estimate (cm²) from a single 6-7 minute whole-body scan. Hologic normative data categorize VAT area as follows:

| VAT Area (cm²) | Risk Category | |---|---| | <100 (women) / <160 (men) | Normal metabolic risk | | 100-160 (women) / 160-220 (men) | Elevated risk | | >160 (women) / >220 (men) | High risk |

These categories are internally validated but should be interpreted alongside clinical context, not as standalone diagnostic thresholds.

What High VAT Means for Health

Elevated VAT is not simply a marker. It is an active driver of cardiometabolic pathology through several interrelated mechanisms.

Insulin Resistance and Type 2 Diabetes

VAT-derived free fatty acids suppress insulin receptor signaling in skeletal muscle and increase hepatic gluconeogenesis. The Framingham Heart Study offspring cohort (N=3,001) showed that each standard-deviation increase in CT-measured visceral fat was associated with a 2.3-fold higher odds of incident type 2 diabetes over 7 years after adjustment for BMI (Fox et al., PMID 17517856).

Cardiovascular Disease Risk

VAT produces interleukin-6, TNF-alpha, and resistin, all of which promote endothelial dysfunction and atherosclerotic plaque progression. A meta-analysis of 11 prospective cohort studies (total N=15,510, mean follow-up 9.5 years) found that high VAT area was associated with a 1.73-fold higher risk of major adverse cardiovascular events (MACE) independent of traditional Framingham risk factors (Gong et al., PMID 26268923).

Hormonal Consequences

Excess VAT converts androgens to estrogens via aromatase enzyme activity, lowering testosterone in men and creating relative androgen excess in women with PCOS. In men, this creates a self-perpetuating cycle: low testosterone drives further visceral fat gain, and visceral fat further suppresses testosterone.

How to Lower Visceral Adipose Tissue

Reducing VAT requires targeting it specifically. Total-weight-loss strategies generally reduce VAT, but the magnitude of VAT reduction varies substantially by intervention type.

Caloric Restriction and Diet Composition

A 500-750 kcal daily deficit reduces VAT preferentially over subcutaneous fat in most intervention studies. A randomized controlled trial comparing Mediterranean diet to a low-fat control diet (N=278, 18 months) found that the Mediterranean group lost 22% more VAT despite similar total weight loss (Shai et al., NEJM 2008, PMID 18635428). Lower-carbohydrate diets may produce slightly greater early VAT reduction because they suppress hepatic lipogenesis directly.

Aerobic Exercise

150 minutes per week of moderate-intensity aerobic exercise reduces VAT by 3-5% even without caloric restriction. A meta-analysis of 15 RCTs (N=852) published in Obesity Reviews showed that aerobic exercise produced a mean VAT reduction of 6.1 cm² over 12 weeks compared to inactive controls (Ismail et al., PMID 21951360). Resistance training alone reduces VAT less reliably, but combined aerobic-plus-resistance programs consistently outperform either alone.

GLP-1 Receptor Agonists

Semaglutide 2.4 mg subcutaneous once weekly (Wegovy) produced a 14.9% mean total body weight loss at 68 weeks versus 2.4% with placebo in STEP-1 (N=1,961) (Wilding et al., NEJM 2021, PMID 33567185). DEXA sub-studies from STEP-1 showed that approximately 30-35% of the weight lost was visceral fat. Tirzepatide 15 mg (Zepbound) produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539) (Jastreboff et al., NEJM 2022, PMID 35658024), with body-composition data showing disproportionate VAT reduction relative to total fat loss.

The Endocrine Society 2024 Obesity Pharmacotherapy Guideline states: "GLP-1 receptor agonists produce clinically meaningful reductions in visceral adipose tissue that are proportionally greater than reductions in total body fat, supporting their use in patients whose primary risk driver is visceral fat accumulation."

Testosterone Replacement Therapy (TRT) in Hypogonadal Men

Low testosterone is both a cause and a consequence of elevated VAT. A meta-analysis of 58 RCTs (N=3,974) showed that testosterone therapy in hypogonadal men reduced VAT by a mean of 4.7 cm² (95% CI 2.9-6.5 cm², P<0.001) and reduced waist circumference by 2.6 cm compared to placebo (Corona et al., PMID 27716917). The effect is meaningful but smaller than that of GLP-1 agonists or substantial caloric deficit. TRT is best used as part of a broader metabolic intervention in men with confirmed hypogonadism, not as a primary fat-loss strategy.

Estrogen Therapy in Postmenopausal Women

Estrogen decline at menopause shifts fat distribution centrally. Observational and randomized data from the Women's Health Initiative (WHI) and smaller RCTs suggest that systemic estrogen therapy attenuates VAT accumulation in early postmenopause, though effect sizes vary by route, dose, and timing of initiation (Greendale et al., PMID 10202374). The menopause hormone therapy decision should incorporate multiple factors beyond VAT alone.

How to Raise Visceral Adipose Tissue (and Why This Almost Never Applies)

The query "how to raise VAT" most often comes from patients who have been told their VAT is low and are confused about whether that is bad. Low VAT is not a clinical problem. No guideline recommends increasing visceral fat for any therapeutic purpose.

When Low VAT Might Appear

Very low VAT readings sometimes appear in athletes with very low total body fat, in patients with lipodystrophy syndromes (where fat cannot be stored normally, leading to metabolic complications despite low measured VAT), or as a measurement artifact from incorrect DEXA positioning. A patient with lipodystrophy may have paradoxically severe insulin resistance despite low VAT because of ectopic fat deposition in muscle and liver.

If a low VAT result is unexpected, confirm correct DEXA acquisition technique and rule out lipodystrophy before interpreting the value as straightforwardly reassuring.

Interpreting VAT Results in Clinical Context

A VAT number without clinical context is incomplete. Use the following framework to make VAT results actionable.

Pairing VAT with Metabolic Lab Work

An elevated VAT finding gains clinical weight when it accompanies:

• Fasting triglycerides >150 mg/dL
• HDL-C <40 mg/dL (men) or <50 mg/dL (women)
• Fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%
• Elevated fasting insulin with HOMA-IR >2.5
• Elevated ALT or ultrasound-confirmed hepatic steatosis

When two or more of these accompany high VAT, the case for intensive metabolic intervention is strong.

Serial VAT Measurement

VAT responds to intervention within 12-16 weeks of caloric restriction or GLP-1 agonist therapy, making repeat DEXA at 6-month intervals a reasonable strategy for monitoring treatment response. A reduction of 10-15% in VAT area over 6 months correlates with measurable improvements in fasting insulin and triglycerides in most intervention studies.

Communicating Results to Patients

Patients respond better to VAT data than to BMI alone because visceral fat imaging is concrete and mechanistic. Showing a patient that their VAT is 185 cm² (above the high-risk threshold for their sex) and explaining its direct connection to their fasting glucose of 108 mg/dL often produces stronger motivation for lifestyle change than a BMI number.

The AACE 2023 Obesity Algorithm notes: "Communicating body-composition data, including visceral fat estimates, to patients as part of a collaborative care discussion improves patient engagement with lifestyle and pharmacologic interventions."